Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595996 | 1.00 | EGFR (0.44) | EGFRPLGPLAUPLATTRPA1 | |
| SCHEMBL31595916 | 0.88 | EGFR (0.44) | EGFRPLAUTRPA1CYP1A2CYP2C19 | |
| SCHEMBL6436780 | 0.88 | EGFR (0.44) | EGFRPLAUTRPA1CYP1A2CYP2C19 | |
| SCHEMBL12386876 | 0.85 | TRPA1 (0.47) | PLGPLAUPLATTRPA1CYP1A2 | |
| SCHEMBL31596134 | 0.81 | TRPA1 (0.46) | TRPA1CYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL7213549 | 0.81 | TRPA1 (0.46) | TRPA1CYP1A2CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL7219345 | 0.81 | ALDH1A1 (0.40) | PLAUPLATTRPA1CYP1A2CYP2C19 | |
| SCHEMBL1093339 | 0.80 | TRPA1 (0.54) | PLAUTRPA1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL15476305 | 0.79 | LMNA (0.47) | PLGPLAUPLATCYP3A4ALDH1A1 | |
| SCHEMBL9998100 | 0.78 | ABCG2 (0.45) | TRPA1CYP1A2CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6534535-B1 | Administering indole derivative as anticoagulant | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2001012600-A9 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6399627-B1 | ANTICOAGULANTS; PROTHROMINASE, SERINE PROTEASE INHIBITOR; ACRYLAMIDE DERIVATIVES | COR THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1189879-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1159264-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| WO-2001012600-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000047554-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | EGFR 4474/4885PLG 141/4885PLAU 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.